IE920206A1 - Monoclonal antibodies to elam-1 and their uses - Google Patents

Monoclonal antibodies to elam-1 and their uses

Info

Publication number
IE920206A1
IE920206A1 IE020692A IE920206A IE920206A1 IE 920206 A1 IE920206 A1 IE 920206A1 IE 020692 A IE020692 A IE 020692A IE 920206 A IE920206 A IE 920206A IE 920206 A1 IE920206 A1 IE 920206A1
Authority
IE
Ireland
Prior art keywords
immunoglobulin
cells
antibodies
antibody
patient
Prior art date
Application number
IE020692A
Other languages
English (en)
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of IE920206A1 publication Critical patent/IE920206A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
IE020692A 1991-01-24 1992-01-23 Monoclonal antibodies to elam-1 and their uses IE920206A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64587891A 1991-01-24 1991-01-24
US73303391A 1991-07-22 1991-07-22

Publications (1)

Publication Number Publication Date
IE920206A1 true IE920206A1 (en) 1992-07-29

Family

ID=27094802

Family Applications (1)

Application Number Title Priority Date Filing Date
IE020692A IE920206A1 (en) 1991-01-24 1992-01-23 Monoclonal antibodies to elam-1 and their uses

Country Status (11)

Country Link
EP (1) EP0568631A4 (fr)
JP (1) JPH06505253A (fr)
AU (1) AU1269092A (fr)
CA (1) CA2100681A1 (fr)
IE (1) IE920206A1 (fr)
IL (1) IL100764A0 (fr)
NO (1) NO932672L (fr)
NZ (1) NZ241399A (fr)
OA (1) OA09809A (fr)
SK (1) SK77393A3 (fr)
WO (1) WO1992012729A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
ATE239506T1 (de) * 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
EP0602290B1 (fr) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antigène de surface du virus de l'hépatite B conjugué à des anticorps et utilisation d'un tel conjugué
US5723116A (en) * 1995-01-06 1998-03-03 University Of South Florida Decreased mortality of severe acute pancreatitis following proximal cytokine blockade
WO1996040942A1 (fr) * 1995-06-07 1996-12-19 Cytel Corporation Anticorps humanises anti-e-selectine
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
BR9912053A (pt) 1998-07-13 2001-04-03 Univ Texas Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
CN1356913A (zh) 1998-12-18 2002-07-03 杜邦药品公司 玻连蛋白受体拮抗剂药物
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
AU2371400A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
KR20110074850A (ko) * 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
KR20220131293A (ko) 2020-01-24 2022-09-27 화이자 인코포레이티드 항-e-셀렉틴 항체, 조성물 및 사용 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002860A1 (fr) * 1988-11-14 1990-05-14 Michael A. Gimbrone Anticorps specifiques de l'elam-1 et application
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)

Also Published As

Publication number Publication date
CA2100681A1 (fr) 1992-07-25
AU1269092A (en) 1992-08-27
SK77393A3 (en) 1994-12-07
EP0568631A4 (fr) 1995-04-05
NO932672L (no) 1993-09-23
IL100764A0 (en) 1992-09-06
NZ241399A (en) 1994-06-27
JPH06505253A (ja) 1994-06-16
WO1992012729A1 (fr) 1992-08-06
EP0568631A1 (fr) 1993-11-10
OA09809A (en) 1994-04-15
NO932672D0 (no) 1993-07-23

Similar Documents

Publication Publication Date Title
IE920206A1 (en) Monoclonal antibodies to elam-1 and their uses
Puri et al. Sialomucin CD34 is the major L-selectin ligand in human tonsil high endothelial venules.
JP3691467B2 (ja) セレクチンリガンド
JP3490443B2 (ja) 血管形成阻害性抗体
CA2210620C (fr) Anticorps anti-cd30 prevenant le clivage proteolytique et la liberation de l'antigene cd30 membranaire
US7071310B1 (en) Antibody against the human toll- like receptor 2 (tlr2) and uses thereof
JP2002114710A (ja) 抗腫瘍剤と共にモノクローナル抗体を用いた治療剤
JP2000325092A (ja) 細胞接着蛋白質と糖質リガンドとの間の相互作用阻害に使用し得る抗体
EP0504327B1 (fr) Emplois therapeutiques de la region hypervariable de l'anticorps monoclonal m195 et de ses structures
CA2134966C (fr) Anticorps specifiques contre de multiples molecules d'adhesion
JPH06507927A (ja) 内皮結合のための化合物及び方法
US5403919A (en) Method to control leukocyte extravasation
JPH08503360A (ja) Ｐ−セレクチンに対する抗体及びその利用
Root Leukocyte adhesion proteins: their role in neutrophil function.
EP0303463B1 (fr) Méthode pour contrôler l'extravasation des leucocytes
CA2095404A1 (fr) Purification et caracterisation d'un recepteur d'adhesion specifique de la region csvtcg d'une cellule tumorale
EP0434685A1 (fr) Endotoxine bacterienne gram negative bloquant des anticorps monoclonaux
WO1994015641A1 (fr) Procede de modulation de la migration transendotheliale des cellules favorisant l'inflammation et procedes connexes de mesure de cette migration
CA2182215A1 (fr) Anti-inflammatoire contenant des anticorps monoclonaux ayant une reactivite avec les chaines de sucre sialyl-lewis x prenant naissance dans la membrane des cellules hemangioendotheliales
WO1997030173A1 (fr) Anticorps monoclonal reconnaissant les antigenes presents a la surface des cellules endotheliales d'un vaisseau tumoral
EP0584273B1 (fr) Anticorps reconnaissant le ligand de cellules endotheliales du leucocyte cr3
WO1993002698A1 (fr) Anticorps monoclonaux contre la molecule-1 d'adhesion aux leucocytes
WO1996011012A1 (fr) Ligand pour l-selectine des cellules hematopoietiques (hll) et therapie associee
JPH06508991A (ja) リンパ細胞に結合した表面タンパク質に対するモノクローナル抗体
Klaich et al. Characterization of a monoclonal antibody recognizing a 138 kDa glioblastoma-associated antigen

Legal Events

Date Code Title Description
FC9A Application refused sect. 31(1)